Digital Edition

Ophthalmology Times: November/December 2025
Volume: 50
Issue: 6

Ophthalmology Times: September/October 2025
Volume: 50
Issue: 5

Ophthalmology Times: July/August 2025
Volume: 50
Issue: 4

Ophthalmology Times: May/June 2025
Volume: 50
Issue: 3

Ophthalmology Times: March/April 2025
Volume: 50
Issue: 2

Ophthalmology Times: January/February 2025
Volume: 50
Issue: 1

Ophthalmology Times: December 2024
Volume: 49
Issue: 12

Ophthalmology Times: November 2024
Volume: 49
Issue: 11

Ophthalmology Times: October 2024
Volume: 49
Issue: 10

Ophthalmology Times: September 2024
Volume: 49
Issue: 9

Ophthalmology Times: August 2024
Volume: 49
Issue: 8

Ophthalmology Times: July 2024
Volume: 49
Issue: 7

Ophthalmology Times: June 2024
Volume: 49
Issue: 6

Ophthalmology Times: May 2024
Volume: 49
Issue: 5

Ophthalmology Times: April 2024
Volume: 49
Issue: 4

Ophthalmology Times: March 2024
Volume: 49
Issue: 3

Ophthalmology Times: February 2024
Volume: 49
Issue: 2

Ophthalmology Times: January 2024
Volume: 49
Issue: 1

Ophthalmology Times: December 2023
Volume: 48
Issue: 12

Ophthalmology Times: November 2023
Volume: 48
Issue: 11

Ophthalmology Times: October 2023
Volume: 48
Issue: 10

Ophthalmology Times: September 2023
Volume: 48
Issue: 9

Ophthalmology Times: August 2023
Volume: 48
Issue: 8

Ophthalmology Times: July 2023
Volume: 48
Issue: 7

Ophthalmology Times: June 2023
Volume: 48
Issue: 6

Ophthalmology Times: May 2023
Volume: 48
Issue: 5

Ophthalmology Times: April 2023
Volume: 48
Issue: 4

Ophthalmology Times: March 2023
Volume: 48
Issue: 3

Ophthalmology Times: February 2023
Volume: 48
Issue: 2

Ophthalmology Times: January 2023
Volume: 48
Issue: 1
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5



.png)


